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Responses of in vivo renal microvessels to dopamine. The split hydro-
nephrotic kidney preparation was used to directly observe the effects of
locally applied dopamine on the in vivo diameters of renal vessels.
Dopamine (I x l0' to 3 x 10-' at) produced a concentration—depend-
ent dilation of the arcuate and interlobular arteries and afferent arteri-
oles. Efferent arterioles near the glomeruli also dilated to dopamine but
the dilation was less than that of the preglomerular vessels. Higher
dopamine concentrations (3 x i0- and I )< i0' M) produced more
variable effects, with a tendency for the arcuate and interlobular
arteries and the afferent and efferent arterioles away from the glomeruli
to decrease in diameter. After pretreatment with haloperidol, dopamine(1 x l0 to I x 10' at) did not dilate any pre- or postglomerular
vascular segment, but the tendency for pre- and postglomerular con-
strictions with higher dopamine concentrations were not abolished.
Pretreatment with phentolamine and propranolol enhanced the dilator
response of the pre- and postglomerular vessels (except the afferent
arterioles near glomeruli and efferent arterioles near welling points) to
dopamine (3 x 10 ' and 1 x l0 M), and abolished the reductions in
diameter produced by the high dopamine levels. These data indicate
that the dilator effect of dopamine is mediated by interactions with
specific dopaminergic receptors, while alpha and beta adrenergic recep-
tors appear to mediate a constrictor influence observed with high
dopamine concentrations. The overall effect of dopamine on the renal
vessel diameters thus appears to depend on the balance of dilator and
constrictor stimuli mediated by multiple receptors.
As early as 1942 Holtz and Credner [1] recognized that
dopamine produced different vascular effects from other cate-
cholamines. Since that time the vasodilator effect of exogenous
dopamine within the kidney has been well demonstrated [2—61.
More recently, the identification of dopaminergic neurons
within the kidney [7, 81 has lead to the speculation that renally
released dopamine may influence intrarenal hemodynamics
under conditions of renal nerve stimulation. Therefore, endog-
enous dopamine may play a physiological role in the regulation
of renal hemodynamics.
The microvascular action(s) of dopamine within the kidney to
decrease renal vascular resistance and thus increase renal blood
flow is not known. It remains uncertain whether dopamine
produces pre- and/or postglomerular dilation to affect the ob-
served increases in renal blood flow, The inaccessibility of the
renal vascular system for direct observation has prevented the
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identification of the precise in vivo microvascular actions of
dopamine, as well as other vasoactive substances.
Numerous investigations [9, 101 have demonstrated that the
effect of exogenous dopamine on renal blood flow is dependent
on the rate of intravenous infusion. In general, low dopamine
infusions increase renal blood flow, while higher infusion rates
tend to decrease renal blood flow. Studies [11—16] utilizing
pharmacological antagonists to dopaminergic receptors indicate
that the vasodilator effects are mediated by dopaminergic
receptors, specifically the DA1 type [17]. Dopaminergic recep-
tors may also be involved in the vasoconstrictor effects of high
dopamine infusions [10, 16]. Furthermore, the reductions in
renal blood flow associated with higher rates of dopamine
infusion have been shown to be attenuated or abolished by
inhibitors of alpha [18—201 and/or beta [2 1—23] adrenergic recep-
tors, suggesting adrenoceptor involvement. Thus, the overall
effect of exogenous dopamine on the renal circulation may to be
determined by the balance of vasodilator and vasoconstrictor
stimuli mediated by dopaminergic and adrenoceptor receptors.
In the present study, the split hydronephrotic kidney prepa-
ration [241 was used to directly observe the in vivo effects of
locally applied dopamine on the diameters of pre- and
postglomerular vessels, The suspension of the kidney in a
controlled bath allowed for the topical application of dopamine
in concentrations which did not influence the systemic blood
pressure. Thus, the indirect, autoregulatory responses of the
vessels due to changes in blood pressure were avoided. In the
present study we also examined the role of dopaminergic
receptors, alpha and beta adrenoceptors, to mediate the effect
of dopamine on each renal vascular segment.
Methods
Induction o.f hydronephrosis
Female Wistar—Furth rats (150 to 200 g) were anesthetized
with pentobarbital (40 mg/kg, i.p.). Unilateral hydronephrosis
was induced by permanently ligating the left ureter and tempo-
rarily occluding (60 mm) the left renal artery.
Preparation of kidney for microvascular observation
Acute microvascular experiments were conducted on these
animals at least nine weeks following the surgery to induce
hydronephrosis. The rats were anesthetized with thiobarbital
(mactin, BYK, 100 mg/kg, i.p.) and were placed on a heating
pad to maintain rectal temperature between 37 and 37.5°C with
the aid of a feedback control system. A polyethylene catheter
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was inserted into the trachea to maintain a patent airway, into
the left carotid artery for continuous measurement of arterial
blood pressure, and into the jugular vein for continuous infusion
of isotonic saline at a rate of 0.06 mllmin.
The left hydronephrotic kidney, exposed by a flank incision,
was split along the greater curvature using a thermal cautery.
The cut edge was sutured to a semicircular wire form to
outstretch the medial half of the kidney to its in situ dimensions.
The rat was then placed on a board with a specially designed
bath. The outstretched kidney, with intact blood flow from the
animal, was placed in the bath by anchoring the wire form to
bottom of the bath. The bath was then sealed and filled with an
isoionic and isocolloidal solution (Raemaccel) warmed to 37.0
to 37.5°C by an automatic heating system in the tissue bath. The
rat board was mounted on the stage of a light microscope and
light was passed through the kidney to visualize the microves-
sels with a Leitz Ultropac Objective UO-55 (water immersion).
The images of the microvessels were displayed on a calibrated
television monitor with a high sensitive camera. The microvas-
cular images were recorded on line by a videotaping devise for
later analysis of changes in vessel diameters.
Selection of microvessels and sites of diameter measurement
The blood flow throughout the entire kidney was examined
under the light microscope to confirm that the kidney was well
perfused. A single glomerulus was selected having rapid blood
flow through all glomerular capillary pathways. To confirm that
blood flow to this glomerulus was rigorous, lissamine green dye
was injected as a bolus into the jugular vein. The time between
the injection of the dye and the appearance of the dye in the
capillaries of the glomerulus was measured, if the dye appeared
in the glomerulus within 2.7 sec after injection, the flow to the
selected glomerulus was considered adequate (based on the
appearance of lissamine green dye in the efferent arterioles on
the cortical surface of normal Wistar rat kidneys [251).
A single efferent, afferent, interlobular, and arcuate vessel
was identified based upon the branching pattern of the vessels
from the selected glomerulus. In all experiments, vessel diam-
eters were measured at the following sites: I) the arcuate artery
at a proximal site near to the interlobar artery and at the most
point distal site near the branching point of the terminal interlobular
artery; 2) the interlobular artery at a proximal site near its
branching point from the arcuate and at a distal site near the
branching point of the terminal afferent arteriole; 3) the afferent
arteriole at a proximal site near to the interlobular artery and a
distal site at the narrowest segment before entering the glomer-
ulus; and 4) the efferent arteriole at a site within 50 m of the
glomerulus and at a distal site near to the welling point. Refer to
Figure 1 for an illustration of a typical vascular branching
pattern and an indication of the points of diameter measure-
ments. This drawing was made from the actual television
recordings of in vivo microscopic observations shown in Figure
2 (a—f).
Experimental protocols
Approximately one hour after the preparation of the kidney
for microvascular observation, one of the following experimen-
tal protocols was initiated.
Experimental series I. This series of experiments was con-
ducted to evaluate the effect of several bath concentrations of
dopamine on the diameters of the microvessels (protocol A) and
to determine the role of specific dopaminergic receptors in
mediating the action of dopamine (protocol B). A third protocol
(protocol C) was performed to evaluate the stability of the
microvascular diameters over a period of time equivalent to the
duration of protocols A and B. Protocols A, B and C were
conducted on three separate groups of nine, five and five rats
per group, respectively.
Protocol A. Dopamine alone: Microvascular diameters were
measured twice during a 10 minute control period. Dopamine
was added to the tissue bath to establish five bath concentra-
tions ranging from 1 x l0 to 1 >< l0 M. Microvascular
diameters were measured 15 minutes after each addition of
dopamine. After the highest dopaminc concentration, the bath
was drained and the kidney was washed with fresh, drug—free
Haemaccel solution. The vessel diameters in the absence of
dopamine were again measured after one hour.
Protocol B. Inhibition of dopamine receptors: Following the
measurement of control vessel diameters, haloperidol (Haldol R)
was added to the tissue bath (bath concentration of I x iO M).
Vessel diameters were measured 15 minutes after the applica-
tion of haloperidol. Then dopamine was added to the bath as
described in protocol A with haloperidol remaining in the bath.
After completing the dose—response curve, the bath was
a. arcuata
near a. interlobaris
a. arcuata near
a. interlobularis
Fig. I. A diagramatic sketch of the renal ,nicrovascular branching
pattern and indications (arrows) of the regions where the diameters
were measured for the arcuate and interlobular arteries, and the
afferent and efferent arterioles. Drawn by Coloma Fester.
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Fig. 2. Photos of television monitor images of the renal microvasculature used to produce Figure 1. A—arcuate artery, B—interlobular artery,
C—interlobular artery and a branching afferent arteriole, D—afferent arteriole near to the glomerulu, E—efferent arteriole near to the glomerulus,
and F—efferent arteriole at the welling point. The arrows in photos D and F point in the direction of blood flow. The full horizontal length of each
picture is 130 gin.
washed and filled with fresh, drug—free solution. One hour later
vessel diameters were again measured.
Protocol C. No drug experiment: The stability of the micro-
vascular diameters was examined during a period of time
equivalent to that of protocols A and B, Dopamine—free,
haemaccel solution was added to the tissue bath at the times in
which dopamine was added in protocol A. Microvascular
diameters were measured 15 minutes after each application of
dopamine—free solution.
Experi,nental series II. These experiments were designed to
determine if the microvascular effect of dopamine on any
microvascular segment was mediated by alpha or beta adrener-
gic receptors. Protocols A and B were conducted on the
kidneys of two separate groups of rats (six rats per group).
Protocol A. Inhibition of alpha—adrenergic receptors: Control
diameters were measured then phentolamine (Regitin) was
added to the bath to establish a concentration of 1 x iO M.
The effect of phentolamine alone, on vessel diameters was
a
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determined 10 minutes after adding the drug. Dopamine was
then added to the bath in increasing concentrations (as de-
scribed for protocol A of Series I) in the presence of
phentolamine. Vessel diameters were measured 15 minutes
after adding each dopamine concentration and also after a one
hour equilibration period in drug—free solution.
Protocol B. Inhibition of beta—adrenergic receptors: Propran-
olol-HCI (Dociton) was added to the bath (bath concentration of
1 x 10-6 M) following a 15 minute control period. Then in the
presence of propranolol, the bath concentration of dopamine
was sequentially increased according to the procedure outlined
in protocol A of Series I.
Drug preparation
All the drugs used in this study were prepared daily. To avoid
oxidation of dopamine, the solution was prepared just prior to
its use and was stored in a dark environment.
Statistical analysis
The data are presented as mean SEM. Paired t-tests were
used to determine significant differences between the initial
control diameters and the diameters after adding dopamine,
alone or following pretreatments such as haloperidol, phentol-
amine, or propranolol. As analysis of variance was used to
compare the extent of dilation produced by dopamine alone
with the dilation induced by dopamine following pretreatment
with haloperidol, phentolamine or propranolol. Duncans multi-
ple range test was used to identify differing mean values,
Results
The mean initial luminal diameters (± SEM, Fig. 3) of the
various vascular segments for all 30 rats of the study were: the
arcuate (proximal) 42 2 microns and the arcuate (distal)
21 1 microns, the interlobular artery = 12 1 microns, the
afferent arteriole near to interlohular = 9 1 microns and near
the glomerulus = 8 1 microns, the efferent arteriole near the
glomerulus = 12 1 microns and near the welling point = 16
1 microns. In eight experiments, the very narrow region of the
efferent arteriole as the vessel exits, the glomerulus could be
clearly visualized. The mean diameter of the efferent segment
was 4 2 microns. In the absence of any drug treatment
(Experimental series I, protocol C), the diameters of all the
vessel segments from six rats did not significantly change (P >
0.05), but remained constant over a period of time equivalent to
the duration of the drug experimental protocols. The systemic
blood pressure of the rats (mean for all 30 rats was 120 4 mm
Hg) also remained constant during the topical application of all
drugs.
Effects of dopamine alone
Dopamine (I x 106 to 3 x l0— M) produced a concentra-
tion—dependent increase in the diameter of the preglomerular
vessels (Fig. 4) as well as the efferent arteriole near to the
glomerulus (Fig. 5). The dilator responses of all preglomerular
vessels were greater than that of the efferent arteriole. Of the
preglomerular vessels, the arcuate artery (proximal) gave the
greatest increase in diameter (increased by 27 10% above the
initial control diameter) compared with the 9 2% increase in
the diameter of the efferent arteriole near the glomerulus. The
efferent arterioles near the welling points (Fig. 5), however, did
not significantly increase (P > 0.05) in diameter with any
dopamine bath concentration.
A bath concentration of 1 x l0- M dopamine dilated (P <
0.05) most preglomerular segments, but the dilations were not
greater than the dilations produced by lower dopamine concen-
trations. However, this dopamine concentration (1 x l0 M)
did not significantly affect the diameter of the efferent arteriole
at either site. Higher bath concentrations of dopamine (3 x
and I x l0 M) tended to reduce the diameter of the arcuate
and interlobular arteries (Fig. 4), the afferent arterioles near the
interlobular arteries, and the efferent arterioles near the welling
points (Fig. 5). However, the reductions in diameter were
significant only for the distal segment of the arcuate arteries and
the efferent arteriole near the welling points. Unlike the other
preglomerular sites, the diameter of the afferent arterioles near
the glomeruli was not decreased by these higher dopamine
concentrations.
For technical reasons, the effect of dopamine on the very
narrow region of the efferent arteriole near to the glomerulus
was not determined in the present study. However, because
this narrow postglomerular segment probably represents a
significant, high resistance region,the action of dopamine at this
site may be important to its overall intrarenal hemodynamic
effect.
Effect of dopamine after dopamine receptor blockade
Haloperidol, added topically to the kidney, did not signifi-
cantly alter the diameter of any vascular segment (Table 1).
However, haloperidol pretreatment did attenuate the dilator
effect of low dopamine concentrations (1 X 106 to 1 X iO M)
on the arcuate (both sites) and interlobular arteries (Fig. 4), the
afferent arterioles (at both sites) and the efferent arterioles near
the glomeruli (Fig. 5).
The tendency for preglomerular vessels (except afferent
arterioles near glomeruli) to constrict to the higher dopamine
concentrations (3 x l0 and 1 x l0 M) was attenuated but
E
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Fig. 3. A plot of the initial diameters (mean SEM) of the renal
vascular segments measured in the hydronephrotic kidney of 30 rats.
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Fig. 4. Bar graph showing the percent changes (mean sEJ'nl in arcuate and interlobular artery diameters from the initial control diameters
following the topical application of dopamine alone (bath concentrations of! x IO to I X 1O M or dopamine following pretreatment with either
haloperidol, phentolamine or propranolol. Diameters following a one hour re-equilibration period in drug—free solution are labelled controls (right).
Symbols are: • dopamine; haloperidol and dopamine; At phentolamine and dopamine; LI propranolol and dopamine; C) significantly different
from dopamine; * P 0.05.
not abolished by haloperidol pretreatment. The constriction of
the efferent arterioles near the welling points was not altered by
haloperidol.
Vessels returned to their initial resting diameters after the one
hour equilibration time in the drug—free solution.
Effect of dopamine after aipha—adrenergic receptor blockade
Vessel diameters were not significantly altered (P > 0.05)
after a 10 minute exposure to phentolamine alone (Table 1). In
the presence of phentolamine, dopamine (1 x 106 to 1 x iO
M) induced concentration—dependent increases in the diameter
of the preglomerular vessels (Fig. 4) and the efferent arteriole
near the glomerulus (Fig. 5), which were often greater than the
dilations to dopamine alone. However, the dopamine—induced
dilation of the afferent arterioles near the glomeruli tended to be
lessened by prior treatment with phentolamine.
With the higher dopamine concentrations (3 x 10 and I x
l0— M), the constriction of the preglomerular vessels (Fig. 4)
and the efferent arterioles near the welling points (Fig. 5) was
either attenuated or abolished by phentolamine pretreatment,
and the vessels gave augmented dilator responses to dopamine.
Similarly, the efferent arterioles near the glomeruli exhibited
greater dilation to these high dopamine concentrations follow-
ing phentolamine pretreatment than to dopamine alone.
Following the one hour re-equilibration period in the
drug—free solution, the interlohular arteries remained signifi-
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Fig. 5. Bar graph representing the percent changes (mean SEM in the diameter of the afferent and efferent arterioles following topical
application of dopamine alone or following pretreatment with either haloperidol, phentolamine or propranolol. Symbols are the same as Figure
4.
cantly dilated. The diameters of the arcuate arteries (distal
segment) and afferent arterioles near the interlobular arteries
also tended (P > 0.05) to remain larger than the initial diame-
ters.
Effect of dopatnine after beta—adrenergic receptor blockade
Propranolol alone had no significant effect on vessel diame-
ters (Table 1). In the presence of propranolol, dopamine (1 Xl0 to 3 x l0- s) increased the diameter of the preglomerular
vessels (Fig. 4) and the efferent arteriole near the glomerulus
(Fig. 5) in a concentration—dependent manner. Furthermore,
the dopamine responses of the preglomerular vessels (except
the afferent arterioles near the glomeruli) at certain bath con-
centrations were greater than the control responses to dopa-
mine. A similar trend was observed for the efferent arterioles
near the glomeruli. The afferent arterioles near the glomeruli,
however, gave the same or slightly lesser dilator responses to
dopamine after propranolol.
In the presence of propranolol, the highest dopamine bath
concentration (1 X l0 M) either dilated or produced less
constriction of the preglomerular vessels and the efferent arteri-
oles near the welling points than in the absence of propranolol,
Discussion
A number of studies have demonstrated that the intravenous
administration of exogenous dopamine exerts a dilator effect
within the renal vasculature to increase renal blood flow [2—61.
The more recent identification of dopaminergic nerve terminals
6
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Table 1. Initial diameters of each microvascular segment and the diameters following haloperidol, phentolaniine, or propranolol treatmentsa
Protocol N
Preglomerular Postglomerular
ARC-P ARC-D INT AFF-P AFF-G EFF-G EFF-D
Series I,B Initial diameterAfter haloperidol
(5)
(5)
48 +
49 +
5
7
26 +
25 +
3
3
13 +
12 +
1
1
9 +
9 +
1
1
7 + 1
7 + 1
13 + 2
12 + 2
16 +
16 +
I
2
Series II,A Initial diameterAfter phentolamine
(6)
(6)
55 +
56 +
7
7
24 +
23 +
4
3
11 +
11 +
1
1
10 +
8 +
2
1
8 + 1
8 + 1
13 + 1
13 + 1
15 +
16 +
2
2
Series II,B Initial diameterAfter propranolol
(5)
(5)
38 +
35 +
2
3
19 +
19 +
1
1
II +
11 +
1
I
9 *
S +
I
1
7 + I
7 + I
II + 1
11 + 1
16 +
16 +
I
1
a Values appear as mean SEM microns. N = number of vessels.
Abbreviations are: ARC-P, arcuate arteriole, proximal segment; ARC-D, arcuate arteriole, distal segment; INT, interlobular arteriole; AFF-P,
afferent arteriole, proximal segment; AFF-G, afferent arteriole near glomerulus; EFF-G, efferent arteriole near glomerulus; EFF-D, efferent
arteriole at welling point.
within the kidney [7, 8] has implicated that endogenously
released dopamine may influence intrarenal hemodynamics and
thus play a role in the regulation of glomerular hemodynamics.
Though the effect of neuronally—released dopamine on renal
hemodynamics is unknown, a dilator action has been specu-
lated based on the numerous observations with exogenous
dopamine.
The precise renal microvascular actions of dopamine which
account for the increases in renal blood flow after exogenous
dopamine administration remain speculative. Because of the
location of the pre- and postglomerular vessels deep within the
kidney, it has been impossible to directly observe their in vivo
responses to dopamine. However, with the development of the
split, hydronephrotic kidney preparation [24] it is now possible
to visualize renal vessels by light microscopy. In the present
study, this preparation was used to directly observe the in vivo
responses of pre- and postglomerular vessels to locally applied
dopamine. Furthermore, the hydronephrotic kidney was sus-
pended in a bath so that dopamine could be topically applied to
establish known bath concentrations. Continous measurement
of systemic blood pressure revealed that the dopamine bath
concentrations did not significantly alter the systemic blood
pressure. Thus, the observed changes in vessel diameters
represented the direct action of dopamine distinct from effects
related to myogenically induced dilation.
In our study, dopamine bath concentration from I x 10 to
1 x l0— M dilated the preglomerular vessels in a concen-
tration—dependent manner. Of the preglomerular vessels, the
arcuate artery (proximal segment) gave the greatest percent
increase in diameter. The efferent arterioles near the glomeruli
also dilated significantly, but the increases in diameter were less
than that observed for the preglomerular vessels. The efferent
arterioles near the welling points, however exhibited no signif-
icant dilations. Higher dopamine concentrations (3 x 10 and
I X 10 M) tended to reduce the diameter of preglomerular
vessels except for the affcrent arteriole near to the glomerulus.
Similarly, the diameter of the efferent arterioles near welling
points decreased with these high dopamine concentrations, but
the efferent segment near the glomerulus again exhibited no
significant change in diameter. Therefore, dopamine elicited
different responses from the various microvascular segments,
and the responses of individual segments were dependent on
the dopamine concentration,
Segmental heterogeneity of renal vessels to dopamine has
been previously reported [26]. Edwards utilized a technique in
which renal microvessels were isolated from normal rabbit
kidneys and were perfused to maintain a constant intraluminal
pressure. Using light microscopy, he directly observed the in
vitro responses of interlobular arteries and afferent and efferent
arterioles following the topical application of dopamine.
Edwards reported that all three vascular segments gave
dose—dependent dilator responses to dopamine; however, the
interlobular arteries were less responsive to dopamine than the
afferent and efferent vessels. He also reported that high con-
centrations of dopamine (exceeding l0— M) produced signifi-
cant reductions in the diameter of the interlobular arteries and
afferent arterioles.
In contrast to in vitro observations made by Edwards, we
observed in the present study that the large preglomerular
vessels located away from the glomeruli were more responsive
to dopamine than the afferent and efferent arterioles near the
glomeruli. The differences between our observations and those
of Edwards may relate to many factors such as species differ-
ences between the rats used in the present study and rabbits
used by Edwards. Secondly, an obvious consideration is the
pathological state of the hydronephrotic kidneys of our study in
comparison with the vessels isolated from normal rabbit kid-
neys. In defense of the appropriateness of the hydronephrotic
kidney model for microvascular studies, thorough histological,
electrophysiological, and cytochemical examinations of the
renal vessels of hydronephrotic kidneys [27, 281 have revealed
that the structural and functional integrity of the vessels is
maintained despite atrophy of the tubular system. Thirdly, the
differences in our observations and those of Edwards may
relate to factors which differ between in vitro and in vivo
experimental preparations. One such factor which is known to
differ in the two studies is the degree of constrictor tone (extent
of constriction) of the vessels as well as the nature of the
vascular tone. The isolated vessels of Edwards study which did
not develop spontaneous tone were constricted 60% from their
relaxed diameters with norepinephrine prior to the addition of
dopamine. The dilation induced by dopamine was then opposed
almost exclusively by norepinephrine—induccd constriction. In
contrast, the resting tone of the vessels of the hydronephrotic
kidneys seemed to be less than that of the isolated vessels, since
dilator agents (acetyicholine and calcium antagonists) produced
a 30 to 40% maximum increase in diameter [29]. Furthermore,
the tone of the glomerular vessels of the hydronephrotic kidney
vessels does not appear to relate solely to norepinephrine. The
absence of a significant dilation after exposure to phentolamine
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suggests that the tone of the vessels is not significantly mediated
through alpha receptors. However, the maintanence of a pre-
glomerular dilation after phentolamine wash—out suggests a
long lasting effect of phentolamine and the involvement of alpha
receptors in mediating a constrictor influence. But, the dilation
was submaximal, and the significance of this sustained dilation
to the basal conditions is difficult to interpret because of the
exposure of the vessels to the high dopamine concentrations
which could alter the norepinephrine profile from the initial
state. The vascular tone of the hydronephrotic kidney vessels
appears to be due to other factors. Inhibition of angiotensin 11
receptors results in a dilation of the vessels [301, but the
dilations do not represent maximum dilations. Reductions in
blood pressure by aortic occlusion result in a submaximal
dilation of the preglomerular vessels (unpublished observa-
tions) suggesting a myogenic component to the vascular tone.
Therefore, the differing contribution by norepinephrine, as well
as other undetermined factors, to the vascular tone of both
preparations may account for the differences observed in the
present study and Edwards study.
The biphasic effect of dopamine on the pregiomerular vessels
(dilation with low bath concentrations and constriction with
higher concentrations) which we observed in the present study
and also by Edwards [261, is consistent with previous reports [9,
101 that high intravenous rates of dopamine decrease blood flow
to intact kidneys. This biphasic action appears to result from
the interaction of dopamine with multiple vascular receptors
including adrenergic and dopaminergic receptors (Fig. 6). In the
present study, we conducted experiments to determine the
relative involvement of these receptor types in mediating the
effects of dopamine on the various vascular segments.
In one group of rats the vessels of hydronephrotic kidneys
were exposed to haloperidol, an antagonist of dopamine recep-
tors, prior to the application of dopamine. In the presence of the
dopamine receptor antagonist, the dilator effect of low dopa-
mine concentrations on the preglomerular vessels and at
postglonierular sites near the glomeruli was attenuated. The
inhibition of dopamine receptors also tended to lessen the
constrictor effect of higher dopamine concentrations on the
preglomerular vessels, but the reductions in diameter were not
abolished in all instances. However, the reductions in welling
point diameters with high dopamine doses were not altered by
haloperidol pretreatment. Therefore, the dilator action of dopa-
mine on pre- and postglomerular vessels appears to involve the
interaction of dopamine with its specific receptors. The ten-
dency for attenuation of the constrictor effect of high dopamine
concentrations may reflect inhibition of dopaminergic receptors
which may stimulate renin release [22, 23, 32, 331 or may reflect
a secondary effect of haloperidol to block adrenergic receptors
[311 when administered in high concentrations.
To evaluate the involvement of adrenergic receptors to
mediate the constrictor responses of pregiomerular vessels to
high dopamine bath concentrations, the vessels were treated
with either phentolamine, an alpha receptor antagonist, or
propranolol, a beta adrenergic receptor blocker, prior to dopa-
mine application. The absence of a significant dilation following
phentolamine or propranolol alone suggested that the tone of
the vessels was not due to activation of these receptors.
However, in general, following inhibition of alpha or beta
adrenoceptors there was an enhancement of the dilator re-
sponses of the preglomerular vessels (except proximal arcuate
and afferent arterioles near glomeruli) and the efferent arterioles
near the glomeruli to intermediate dopamine bath concentra-
tions (3 x 10 and I x i0 M). This enhanced effect suggests
that alpha and beta adrenergic receptors were activated and
opposed the dilator effect of dopamine at these sites. Aug-
mented dilator responses by the afferent arterioles near glomer-
uli by beta blockade and not alpha adrenoceptor blockade
suggests that at this preglomerular site events, mediated by the
beta and not alpha receptors, attenuated the dilator effect of
dopamine. With higher dopamine concentrations the tendency
for the preglomerular vessels to constrict was attenuated by
alpha and beta receptor blockade and in many instances the
vessels gave significant dilator responses. This indicates that
activation of alpha and beta adrenergic receptors by the higher
dopamine concentrations mediated, in large part, the tendency
for preglomerular constriction. The constriction of the efferent
arterioles near welling points was only abolished by beta
blockade implicating an involvement of beta and not alpha
receptors in mediating the constrictor response. Thus, the role
of alpha and beta adrenoceptors in modulating the dilator effect
of dopamine was different for the various vascular segments.
This study did not investigate the mechanism whereby alpha
and beta receptors mediate this constrictor influence at specific
vascular regions. However, based on the observations of others
direct stimulation of alpha receptors (alpha-i) by dopamine
[17—20j may account for the involvement of alpha adrenocep-
tors in mediating vasoconstriction. Similarly, dopamine may
directly stimulate beta receptors [21, 22] resulting in the release
of renin and the subsequent formation of angiotensin 11 to
constrict these vessels. Other data [16, 33, 341, however, does
not support the involvement of beta adrenergic receptors in
Haloperidol Phentolam ne
Vasodilation Vasoconstrictj
Fig. 6. A schematic representation of the possible involvement of
dopaminergic, alpha and beta beta adrenergic receptors in mediating
dilator and constrictor eJJcts of dopamine on the renal vessels.
Abbreviation NE is norepinephrine.
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mediating the renin secretory action of dopamine. A third
possibility which is supported by experimental evidence [23, 32,
33] is that dopaminergic receptors, independent of adrenergic
receptors, may stimulate the formation of cAMP within renin
containing cells resulting in the stimulation of renin synthesis
and release. Thus, there remains considerable uncertainty as to
which receptor(s) mediate this action of dopamine. Figure 6
schematically depicts the possible involvement of dopaminergic
and adrenergic receptors in mediating dilator and constrictor
events following exposure to dopamine. Our observations sup-
port the involvement of adrenergic and dopaminergic receptors
in the dopamine constrictor action since inhibition of both
receptors types attenuated the constrictor response of the pre-
and postglomerular vessels. However, the present data suggest
that dopaminergic receptors played a lesser role than adreno-
ceptors in mediating the constrictor tendency of the renal
vessels. Thus, the potency of the dilator and constrictor influ-
ences and the receptors involved will differ for different renal
vascular segments and for different dopamine concentrations.
Given that the constriction of pre- and postglomerular vessels
with the high dopamine concentrations may, in large part, be
due to an angiotensin II effect, our observations imply that
angiotensin II exerts a constrictor action of angiotensin II on
the large preglomerular vessels, as well as the efferent arteriole
close to the glomerulus. In a previous study [33] utilizing the
hydronephrotic kidney, we directly observed a significant con-
strictor response of preglomerular vessels to topically applied
angiotensin II which provides supporting evidence for the
implied preglomerular constriction by angiotensin II in the
present investigation. However, the possibility also exists that
the preglomerular constriction was mediated indirectly by alpha
receptors in response to the release of norepinephrine from
adrenergie nerve terminals due to the action of angiotensin II
[34].
In summary, the present observations provide direct in vivo
evidence that the effect of dopamine to increase renal blood
flow is mediated by a dilator action primarily on preglomerular
vessels away from the glomcrulus. Furthermore, our data
corraborate with observations by others that dopamine inter-
acts with several receptor types within the renal vasculature to
produce an overall vascular effect, which is dependent on the
balance of dilator and constrictor stimuli. At the preglomerular
sites, alpha and beta adrenoceptors appear to play a role in
mediating the constrictor influence while at postglomerular sites
beta receptor alone seem to be involved.
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